Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
…, S Sakata, K Saruwatari, R Sato, S Iyama, T Jodai… - Cancer immunology …, 2020 - AACR
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
…, A Minemura, K Oka, A Hayashi, T Jodai… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies
…, S Iyama, K Akaike, S Hamada, T Jodai… - Journal of clinical …, 2019 - mdpi.com
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …
in immune-related adverse events. Recent case studies have suggested the association …
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti‐PD‐1 immune checkpoint antibody in a lung cancer patient
T Jodai, C Yoshida, R Sato, Y Kakiuchi… - Immunity …, 2019 - Wiley Online Library
… antibody in a lung cancer patient - Jodai - 2019 - Immunity, Inflammation and Disease -
Wiley Online Library … Takayuki Jodai and Chieko Yoshida contributed equally to this work. …
Wiley Online Library … Takayuki Jodai and Chieko Yoshida contributed equally to this work. …
Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control …
…, Y Migiyama, Y Sakamoto, T Jodai… - Therapeutic …, 2017 - journals.sagepub.com
Background: Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP)
therapy has been approved for sepsis-associated acute respiratory distress syndrome, but …
therapy has been approved for sepsis-associated acute respiratory distress syndrome, but …
Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving …
Y Tomita, S Sakata, K Imamura, S Iyama, T Jodai… - Cancers, 2023 - mdpi.com
Simple Summary Gut microbiota is a key regulators of the efficacy of immune checkpoint
inhibitor (ICIs). Thus, manipulating microbiota may enhance cancer treatment outcomes. …
inhibitor (ICIs). Thus, manipulating microbiota may enhance cancer treatment outcomes. …
The risks and benefits of immune checkpoint blockade in anti-AChR antibody-seropositive non-small cell lung cancer patients
…, R Sato, S Nakane, S Sakata, K Takamatsu, T Jodai… - Cancers, 2019 - mdpi.com
Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an
immune response to cancer. However, a disruption of the immune checkpoint function by …
immune response to cancer. However, a disruption of the immune checkpoint function by …
Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive …
…, S Hirooka, K Akaike, K Kojima, T Jodai… - BMC pulmonary …, 2017 - Springer
Background Rapidly progressive interstitial pneumonias (RPIPs) associated with clinically
amyopathic dermatomyositis (CADM) are highly resistant to therapy and have a poor …
amyopathic dermatomyositis (CADM) are highly resistant to therapy and have a poor …
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small …
T Jodai, K Saruwatari, T Ikeda, E Moriyama… - International Journal of …, 2021 - Springer
Background Anti-programmed cell death protein-1/ligand-1 (anti-PD-1/PD-L1) therapy is
promising for patients with non-small-cell lung cancer (NSCLC); however, clinical trials have …
promising for patients with non-small-cell lung cancer (NSCLC); however, clinical trials have …
Negative-predictive value of SUVmax for Ascertaining the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer
…, S Oda, S Shiraishi, K Akaike, K Imamura, T Jodai… - Respiratory …, 2024 - Elsevier
Background Fluorine- 18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed
tomography ( 18 F-FDG PET/CT) is routinely used to stage non-small cell lung cancer (…
tomography ( 18 F-FDG PET/CT) is routinely used to stage non-small cell lung cancer (…